IBB - Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal.
Adv Exp Med Biol. 2020;1219:355-363. doi: 10.1007/978-3-030-34025-4_18.
Ovarian cancer is a silent cancer which rate survival mainly relays in early stage detection. The discovery of reliable ovarian cancer biomarkers plays a crucial role in the disease management and strongly impact in patient's prognosis and survival. Although having many limitations CA125 is a classical ovarian cancer biomarker, but current research using proteomic or metabolomic methodologies struggles to find alternative biomarkers, using non-invasive our relatively non-invasive sources such as urine, serum, plasma, tissue, ascites or exosomes. Metabolism and metabolites are key players in cancer biology and its importance in biomarkers discovery cannot be neglected. In this chapter we overview the state of art and the challenges facing the use and discovery of biomarkers and focus on ovarian cancer early detection.
卵巢癌是一种沉默的癌症,其存活率主要依赖于早期发现。发现可靠的卵巢癌生物标志物对于疾病的管理至关重要,并对患者的预后和生存产生重大影响。尽管 CA125 具有许多局限性,但目前使用蛋白质组学或代谢组学方法学的研究仍在努力寻找替代生物标志物,使用非侵入性的相对非侵入性来源,如尿液、血清、血浆、组织、腹水或外泌体。代谢和代谢物是癌症生物学中的关键因素,其在生物标志物发现中的重要性不容忽视。在本章中,我们概述了使用和发现生物标志物所面临的挑战和现状,并重点关注卵巢癌的早期检测。